This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma
Scientific Reports Open Access 03 April 2024
-
Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma
Leukemia Open Access 12 December 2022
-
Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4
Scientific Reports Open Access 27 September 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. AIRC Press: Lyon France, 2008.
Jares P, Colomer D, Campo E . Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122: 3416–3423.
Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101: 4975–4981.
Cogliatti SB, Bertoni F, Zimmermann DR, Henz S, Diss TC, Ghielmini M, Schmid U . IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome. J Pathol 2005; 206: 320–327.
Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012; 72: 5307–5316.
Ondrejka SL, Lai R, Smith SD, Hsi ED . Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011; 96: 1121–1127.
Espinet B, Ferrer A, Bellosillo B, Nonell L, Salar A, Fernández-Rodríguez C et al. Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry. Clin Cancer Res 2014; 20: 1007–1019.
Vegliante MC, Palomero J, Perez-Galan P, Roue G, Castellano G, Navarro A et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 2013; 121: 2175–2185.
Basso K, Dalla-Favera R . Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev 2012; 247: 72–183.
Papadopoulou V, Postigo A, Sánchez-Tilló E, Porter AC, Wagner SD . ZEB1 and CtBP form a repressive complex at a distal promoter element of the BCL6 locus. Biochem J 2010; 427: 541–550.
Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007; 12: 280–292.
Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R . Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003; 101: 2914–2923.
Basso K, Schneider C, Shen Q, Holmes AB, Setty M, Leslie C, Dalla-Favera R . BCL6 positively regulates AID and germinal center gene expression via repression of miR-155. J Exp Med 2012; 209: 2455–2465.
Camacho FI, García JF, Cigudosa JC, Mollejo M, Algara P, Ruíz-Ballesteros E et al. Aberrant Bcl6 protein expression in mantle cell lymphoma. Am J Surg Pathol 2004; 28: 1051–1056.
Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA 2013; 110: 18250–18255.
Acknowledgements
We are grateful to L Pasqualucci and R Dalla-Favera for providing the pLA/S5 reported construct and pMT2T-HA-BCL6 expressing plasmid. We are grateful to Giovanna Rocador from the Centro Nacional Investigación Oncológica, Madrid, Spain for generously providing us the BCL6 antibody. We are grateful to Xose S Puente for analyzing WGS and WES data. This study has been supported by the Ministerio de Economía y Competitividad (BFU2012-30857 to VA), Fundació La Marató de TV3-Cancer 2013 (20130110 to VA) and the Instituto de Salud Carlos III RTICC (RD12/0036/0036 and PIE13/00033 to EC). Fondo Europeo de Desarrollo Regional. Unión Europea. Una manera de hacer Europa. EC is an ICREA-Academia Researcher.
Author contributions
JP, MCV and AE performed experiments, analyzed data and wrote the manuscript; MLR, PB and DM performed experiments, EC and VA designed research and wrote the manuscript; and all authors reviewed and approved the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Palomero, J., Vegliante, M., Eguileor, A. et al. SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6. Leukemia 30, 1596–1599 (2016). https://doi.org/10.1038/leu.2015.355
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.355
This article is cited by
-
SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma
Scientific Reports (2024)
-
Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma
Leukemia (2023)
-
Detailed characterization of the transcriptome of single B cells in mantle cell lymphoma suggesting a potential use for SOX4
Scientific Reports (2021)
-
Sox11 promotes head and neck cancer progression via the regulation of SDCCAG8
Journal of Experimental & Clinical Cancer Research (2019)
-
CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course
Modern Pathology (2018)